- $365.45m
- $1.64bn
- $1.08bn
Brief: Embecta Reports Third Quarter Fiscal 2026 Financial Results
Brief: Embecta Outlook FY Adjusted EPS USD 0.27 Vs. IBES Estimate USD 1.59
U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
Embecta hits record low after cutting forecast, initiating review
Embecta falls on forecast cut, initiatives review
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
U.S. STOCKS ON THE MOVE-Alibaba, Accenture, energy companies
Brief: Embecta Announces Definitive Agreement To Acquire Owen Mumford Holdings Limited
Embecta rises after agreeing to buy UK device maker Owen Mumford
Brief: Embecta Corp. Reports Fiscal 2025 Fourth Quarter
Insulin syringe maker Embecta's Q4 revenue just misses estimates
Embecta jumps on quarterly results beat
Embecta Corp reports results for the quarter ended June 30 - Earnings Summary
Medical supplies company Embecta beats Q3 estimates, raises FY forecast
Embecta Corp reports results for the quarter ended March 31 - Earnings Summary
Embecta Corp reports results for the quarter ended December 31 - Earnings Summary